Atom Investors’s Perspective Therapeutics CATX Stock Holding History

Atom Investors’s Portfolio CATX Stock Details CATX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-16,815	Closed	-$57.7K	–	609
2025 Q3	$57.7K	Buy	+16,815	New	+$61.3K	﹤0.01%	574
2024 Q2	–	Sell	-55,128	Closed	-$656K	–	503
2024 Q1	$656K	Buy	+55,128	New	+$470K	0.08%	280

Other funds holding CATX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

NWMG

Nicholson Wealth Management Group Charlestown, South Carolina $172M AUM 10.38% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Atom Investors's CATX Position: Q4 2025 in Review

Atom Investors sold out of Perspective Therapeutics (CATX) in Q4 2025, closing a stake of 16,815 shares — an estimated $57.7K sold.

Atom Investors first reported a position in CATX in Q1 2024 and held it in 2 quarters. The position peaked at $656K in Q1 2024. 117 funds tracked by Wall St. Rank hold CATX as of Q4 2025.

Atom Investors reported no remaining Perspective Therapeutics position as of Q4 2025 after selling out during the quarter.
Atom Investors sold 16,815 Perspective Therapeutics shares in Q4 2025, an estimated $57.7K.
Atom Investors first reported a position in Perspective Therapeutics in Q1 2024 and held it in 2 quarters.
Atom Investors's Perspective Therapeutics position peaked at $656K in Q1 2024.
117 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q4 2025.

Based on Atom Investors's 13F filing for Q4 2025, filed 17 Feb 2026.